In the high-stakes world of pharmaceutical development, the journey from laboratory bench to patient bedside is often perilous. Yet, a startling reality exists: thousands of promising, life-altering drug candidates are currently sitting dormant on the shelves of major pharmaceutical corporations. According to Annette Bakker, PhD, CEO of the Children’s Tumor Foundation (CTF), more than 5,000 potential treatments for rare diseases have been mothballed, despite many having already cleared significant hurdles in preclinical development, toxicology screening, or even early-stage clinical trials.
For the rare disease community, these "shelved assets" represent a tragic loss of potential. As the pharmaceutical industry shifts priorities—often driven by mergers, acquisitions, or pivots in commercial strategy—innovative compounds are discarded, leaving patients with limited options. The CTF is now spearheading an ambitious initiative to act as a bridge, rescuing these abandoned assets and shepherding them toward clinical reality.
The Anatomy of a Shelved Asset
To understand why such valuable medical research is abandoned, one must look at the cold calculus of modern pharmaceutical business. Often, a large pharmaceutical company acquires a smaller biotech firm to gain access to a "crown jewel" asset. In the ensuing corporate restructuring, the remaining pipeline—which may contain compounds with immense therapeutic potential for rare, underserved conditions—is deemed non-core. These assets are sidelined, and the associated data, which represents years of labor and millions of dollars in investment, is locked away.
"Shelved assets are our focus because a shelved asset has already undergone a lot of development," Dr. Bakker explains. "A company has often spent hundreds of millions of dollars on them, and they are now written off as a loss. What if we could take those and put them right into clinical trials? We could win all those years of preclinical and toxicology work and go into clinical development almost immediately."
When a biotech company fails or is absorbed, the tragedy is twofold: patients are denied a potential cure, and the scientific community is deprived of the data generated by the project. The CTF seeks to change this by creating a collaborative framework where these assets can be salvaged rather than forgotten.
Chronology of a Success Story: The Path to Gomekli
The effectiveness of the CTF’s model is best illustrated by the development of Gomekli (selumetinib), a treatment for neurofibromatosis (NF). NF is a group of complex genetic conditions characterized by the growth of tumors on nerves throughout the body, often causing significant pain and physical impairment.
- Pre-2017: The CTF identifies MEK inhibitors as a highly promising therapeutic target for neurofibromatosis. The foundation funds early-stage research to prove the efficacy of this class of drugs in NF models.
- The Partnership (2017): Recognizing the potential, Dr. Bakker engages with leadership at Pfizer, including champions like Freda Lewis-Hall and Lara Sullivan. Through persistent advocacy, the CTF facilitates the licensing of a shelved Pfizer asset to a spin-off entity, SpringWorks Therapeutics.
- Clinical Development: With the asset rescued, the team accelerates clinical trials, leveraging the patient-centric networks and data models established by the CTF.
- FDA Approval (2023): The efforts culminate in the FDA approval of the drug for patients with inoperable plexiform neurofibromas, providing a lifeline to those who previously had no pharmacological options.
- Exit and Legacy (2024/2025): The success of SpringWorks leads to its acquisition by Merck KGaA for $3.4 billion, demonstrating that "socially conscious" drug development can also yield significant commercial value, potentially incentivizing future pharmaceutical participation.
The Hurdles of Rare Disease Development
While the Gomekli success story provides a roadmap, scaling this model remains fraught with difficulty. Drug discovery is inherently challenging, but in the realm of rare diseases, every obstacle is magnified tenfold.
The Recruitment Gap
One of the most persistent barriers is patient recruitment. In many rare diseases, the patient population is not only small but geographically dispersed. For a condition like NF, which affects approximately 1 in 2,000 people, the subset requiring specific surgical or pharmacological intervention is even smaller. Filling a clinical trial with a statistically significant number of participants can take years, inflating costs and stalling momentum.
The Institutional "Door"
Despite the proven success of the CTF’s model, Dr. Bakker notes that pharmaceutical companies are often hesitant to open the door to such partnerships. "We are looking for these champions in other companies that are willing to work with us, but the pharma companies we are calling are not opening the door," she admits. Overcoming this cultural inertia—where companies are often protective of their intellectual property, even if they have no intention of developing it—is the next great frontier for patient advocacy groups.
Building a Sustainable Ecosystem
The CTF is not merely acting as a broker; it is building a comprehensive infrastructure designed to ensure that once an asset is acquired, it has the best possible chance of reaching the market.
Preclinical Hubs and Models
The foundation has established a robust, ever-growing network of preclinical models. By maintaining this infrastructure, the CTF ensures that when a pharmaceutical company decides to divest an asset, the foundation is ready to step in. They can immediately transition the compound into their preclinical hub to validate findings and prepare for the rigors of human clinical trials.
Data Transparency and Continuity
By acting as a centralized hub, the CTF preserves data that might otherwise be lost. When a biotech company shutters its operations, the "institutional memory" of their research often vanishes. The CTF’s repository ensures that these findings are curated and accessible, creating a cycle of continuous learning that accelerates the path to future drug candidates.
Implications for the Future of Medicine
The implications of the CTF’s work extend far beyond neurofibromatosis. This model of "nonprofit-driven rescue" could revolutionize the broader pharmaceutical landscape.
- Economic Efficiency: By reclaiming shelved assets, the industry can reduce the staggering waste associated with abandoned drug programs. This represents a more ethical and efficient use of capital, as resources are spent on refinement rather than starting from scratch.
- Patient-Centric Advocacy: The CTF’s ability to mobilize patient networks provides a ready-made cohort for clinical trials. This solves the "recruitment bottleneck" that frequently causes companies to walk away from rare disease programs.
- A New Business Model: The $3.4 billion acquisition of SpringWorks proves that rescuing "orphaned" drugs is not just an act of charity—it is a viable business strategy. This serves as a powerful incentive for pharmaceutical executives to look at their own shelves with a fresh perspective.
Conclusion: The Moral Imperative
As the pharmaceutical industry continues to consolidate, the need for intermediary organizations like the Children’s Tumor Foundation has never been greater. The current system of drug discovery, while technologically advanced, is often hindered by commercial rigidities that prioritize quarterly returns over long-term patient health.
By positioning themselves as a professional, scientifically rigorous partner, the CTF is challenging the industry to rethink how it handles its "forgotten" assets. Every drug sitting on a shelf is a potential story of a patient whose life could be improved or saved. For the thousands of patients suffering from rare conditions, the work being done by Dr. Bakker and her team is more than just research—it is a vital, systematic rescue mission.
The path forward requires more "champions" within the pharmaceutical sector to bridge the gap between corporate divestment and patient need. If the industry can learn to see these shelved assets not as tax write-offs, but as opportunities for collaborative, life-saving innovation, the next decade could witness a renaissance in rare disease treatment.
About the Author
